Clinical trials: Antibody
Advanced Solid Tumors
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average…
- Trial name
- NCT06336707
- Testing
- HS-20089, Adebrelimab, Bevacizumab
- Where
- China
- Volunteers
- 1,048 people
- Sponsor
- Hansoh BioMedical R&D Company
Glioblastoma
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed.
- Trial name
- GLIOSTAR (NCT04573192)
- Testing
- L19TNF, Lomustine
- Where
- 15 sites in France, Germany and 2 more
- Volunteers
- 142 people
- Sponsor
- Philogen S.p.A.
Tetanus
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical…
- Trial name
- NCT00437671
- Testing
- Tetanus Immune Globulin (Human), Diphtheria-Tetanus Toxoids Adsorbed
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Grifols Therapeutics LLC
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United…
- Trial name
- HONUS (NCT05200871)
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 487 people
- Sponsor
- Travere Therapeutics, Inc.
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Multiple Myeloma
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and…
- Trial name
- NCT04036461
- Testing
- CC-99712, BMS-986405
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Prostate Cancer
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of…
- Trial name
- NCT00992186
- Testing
- Carlumab
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 46 people
- Sponsor
- Centocor Research & Development, Inc.
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Solid Tumor, Adult
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
- Trial name
- NCT06265727
- Testing
- CRB-701, Anti-PD-1
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 348 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Non Small Cell Lung Cancer, Small Cell Lung Cancer
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients…
- Trial name
- NCT07253142
- Testing
- HLX43 dose 1, HLX43 dose 2
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Henlius Biotech
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects.
- Trial name
- NCT05559554
- Testing
- AK104 (before the change), AK104 (after the change)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Akeso
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04002622
- Testing
- TQB2450
- Where
- 18 sites in China
- Volunteers
- 1 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Multiple Sclerosis, Relapsing-Remitting
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis.
- Trial name
- ANGEL-MS (NCT03239860)
- Testing
- GNbAC1 Monoclonal Antibody
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 220 people
- Sponsor
- GeNeuro SA
Asthma
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies
- Trial name
- NCT00659659
- Testing
- MEDI-563
- Where
- 11 sites in United States, Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Cutaneous T-Cell Lymphoma
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy
- Trial name
- NCT06285370
- Testing
- Mogamulizumab
- Where
- 8 sites in China
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after…
- Trial name
- NCT06382129
- Testing
- BL-B01D1, Docetaxel
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.